Cargando...
Immune consequences of anti-angiogenic therapyin renal cell carcinoma
Current therapies of renal cell carcinoma (RCC), a highly vascularised tumour, mostly rely on anti-angiogenic treatment options. These include tyrosine kinase inhibitors (TKIs) and anti-VEGF monoclonal antibodies. Although these strategies aim at restraining vascularisation to control tumour growth,...
Gardado en:
| Publicado en: | Contemp Oncol (Pozn) |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Termedia Publishing House
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5885083/ https://ncbi.nlm.nih.gov/pubmed/29628789 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/wo.2018.73878 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|